Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
This study is currently recruiting participants.
Study NCT00684411 Information provided by Dana-Farber Cancer Institute
First Received: May 22, 2008 Last Updated: October 2, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
T Cell Non-Hodgkin Lymphoma
Additional conditions recognized in this trial
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Imatinib mesylate
Additional drug interventions recognized in this trial
Imatinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Novartis
Back to top of Main Content